Your browser does not support JavaScript! TOPICAL CLEANSER (BENZOYL PEROXIDE) SOAP [HARRIS PHARMACEUTICAL, INC.]
DailyMed Logo Header image

Daily Med

Current Medication Information

Options

RxNorm Names

TOPICAL CLEANSER (benzoyl peroxide) soap
[Harris Pharmaceutical, Inc.]


Category DEA Schedule Marketing Status
HUMAN PRESCRIPTION DRUG LABEL unapproved drug other
NOTE:THIS DRUG HAS NOT BEEN FOUND BY FDA TO BE SAFE AND EFFECTIVE, AND THIS LABELING HAS NOT BEEN APPROVED BY FDA. For further information about unapproved drugs, click here.
Drug Label Sections

Rx Only

DESCRIPTION:
Benzoyl Peroxide Topical Cleanser 6% is a topical, gel-based, benzoyl peroxide containing preparation for use in the treatment of acne vulgaris. Benzoyl peroxide is an oxidizing agent that possesses antibacterial properties and is classified as a keratolytic. Benzoyl peroxide (C14H10O4) is represented by the following chemical structure:
Structure
Benzoyl Peroxide Topical Cleanser 6% contains Benzoyl Peroxide USP 6% as the active ingredient, in a vehicle consisting of: carbomer interpolymer type A NF, cetyl alcohol NF, disodium oleamido MEA-sulfosuccinate, edetate disodium USP, glycerin USP, glyceryl stearate/PEG-100 stearate, laureth-12, magnesium aluminum silicate NF, propylene glycol USP, purified water, sodium coco-sulfate, sodium lauroamphoacetate, xanthan gum NF.

CLINICAL PHARMACOLOGY:
The mechanism of action of benzoyl peroxide is not totally understood but its antibacterial activity against Propionibacterium acnes is thought to be a major mode of action. In addition, patients treated with benzoyl peroxide show a reduction in lipids and free fatty acids, and mild desquamation (drying and peeling activity) with simultaneous reduction in comedones and acne lesions. Little is known about the percutaneous penetration, metabolism, and excretion of benzoyl peroxide, although it has been shown that benzoyl peroxide absorbed by the skin is metabolized to benzoic acid and then excreted as benzoate in the urine. There is no evidence of systemic toxicity caused by benzoyl peroxide in humans.

INDICATIONS AND USAGE:
Benzoyl Peroxide Topical Cleanser 6% is indicated for the topical treatment of acne vulgaris.

CONTRAINDICATIONS:
This preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

WARNINGS:
When using this product, avoid unnecessary sun exposure and use a sunscreen.

PRECAUTIONS:
General:
For external use only. If severe irritation develops, discontinue use and institute appropriate therapy. After reaction clears, treatment may often be resumed with less frequent application. These preparations should not be used in or near the eyes or on mucous membranes.

Information for Patients:
Avoid contact with eyes, eyelids, lips and mucous membranes. If accidental contact occurs, rinse with water. Contact with any colored material (including hair and fabric) may result in bleaching or discoloration. If excessive irritation develops, discontinue use and consult your physician.

Carcinogenesis, Mutagenesis, Impairment of Fertility:
Data from several studies employing a strain of mice that are highly susceptible to developing cancer suggest that benzoyl peroxide acts as a tumor promoter. The clinical significance of these findings to humans is unknown. Benzoyl peroxide has not been found to be mutagenic (Ames Test) and there are no published data indicating it impairs fertility.

Pregnancy:
Teratogenic Effects:

Pregnancy Category C: Animal reproduction studies have not been conducted with benzoyl peroxide. It is not known whether benzoyl peroxide can cause fetal harm when administered to a pregnant woman or can effect reproduction capacity. Benzoyl peroxide should be used by a pregnant woman only if clearly needed. There are no available data on the effect of benzoyl peroxide on the later growth, development and functional maturation of the unborn child.

Nursing Mothers:
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be
exercised when benzoyl peroxide is administered to a nursing woman.

Pediatric Use:
Safety and effectiveness in children have not been established.

ADVERSE REACTIONS:
Allergic contact dermatitis and dryness have been reported with topical benzoyl peroxide therapy.

OVERDOSAGE:
If excessive scaling, erythema or edema occurs, the use of these preparations should be discontinued. To hasten resolution of the adverse effects, cool compresses may be used. After symptoms and signs subside, a reduced dosage schedule may be cautiously tried if the reaction is judged to be due to excessive use and not allergenicity.

DOSAGE AND ADMINISTRATION:
Wash affected areas once or twice daily, or as directed by your dermatologist. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10-20 seconds working into a full lather, rinse thoroughly and pat dry. If drying occurs, it may be controlled by rinsing cleanser off sooner or using less often.

HOW SUPPLIED:
Benzoyl Peroxide Topical Cleanser 6% – 6 oz.(170.3 g) bottle, NDC 67405-435-06

Benzoyl Peroxide Topical Cleanser6% – 12oz.(340.2g) bottle, NDC 67405-435-12

Store at 15°–25°C(59°–77°F).

Manufactured for:
HARRIS Pharmaceutical, Inc.
Ft. Myers, FL
33908
877-RX4-DERM
www.HarrisPharmaceutical.com
Logo
Manufactured by:
Groupe Parima
Montreal,QC H4S 1X6
CANADA
Label

TOPICAL CLEANSER 
benzoyl peroxide soap
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:67405-435
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
BENZOYL PEROXIDE (BENZOYL PEROXIDE) BENZOYL PEROXIDE60 mg  in 1 g
Inactive Ingredients
Ingredient NameStrength
CARBOMER INTERPOLYMER TYPE A (55000 CPS) 
CETYL ALCOHOL 
DISODIUM OLEAMIDO MEA-SULFOSUCCINATE 
EDETATE DISODIUM 
GLYCERIN 
GLYCERYL MONOSTEARATE 
POLYOXYL 100 STEARATE 
LAURETH-12 
MAGNESIUM ALUMINUM SILICATE 
PROPYLENE GLYCOL 
WATER 
SODIUM COCO-SULFATE 
SODIUM LAUROAMPHOACETATE 
XANTHAN GUM 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:67405-435-06170.3 g in 1 BOTTLE
2NDC:67405-435-12340.2 g in 1 BOTTLE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other11/18/2010
Labeler - Harris Pharmaceutical, Inc. (617204370)
Registrant - Groupe PARIMA, Inc. (252437850)
Establishment
NameAddressID/FEIBusiness Operations
Groupe PARIMA, Inc.252437850manufacture

Revised: 11/2010
 
Harris Pharmaceutical, Inc.

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services